Document is current
Any future updates will be listed below
-
Authors
Kitai, Hidenori https://orcid.org/0000-0001-6372-846X
Choi, Philip H.
Yang, Yu C. https://orcid.org/0000-0001-8318-1174
Boyer, Jacob A.
Whaley, Adele
Pancholi, Priya https://orcid.org/0009-0000-9863-130X
Thant, Claire
Reiter, Jason
Chen, Kevin
Markov, Vladimir
Taniguchi, Hirokazu
Yamaguchi, Rui https://orcid.org/0000-0003-1224-227X
Ebi, Hiromichi https://orcid.org/0000-0003-3155-7576
Evans, James
Jiang, Jingjing
Lee, Bianca
Wildes, David https://orcid.org/0009-0009-3855-7270
de Stanchina, Elisa
Smith, Jacqueline A. M.
Singh, Mallika https://orcid.org/0009-0003-0234-1589
Rosen, Neal https://orcid.org/0000-0002-8307-654X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA210085)
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 28 June 2024
First Online: 19 July 2024
Competing interests
: N.R. is on the scientific advisory board (SAB) and owns equity in Beigene, Zai Labs, MapKure, Ribon and Effector. N.R. is also on the SAB of Astra Zeneca and Chugai and a past SAB member of Novartis, Millennium-Takeda, Kura, and Araxes. N.R. is a consultant to RevMed, Tarveda, Array-Pfizer, Boeringher-Ingelheim and Eli Lilly. He receives research funding from Revmed, AstraZeneca, Array Pfizer and Boerhinger-Ingelheim and owns equity in Kura Oncology and Fortress. Y.C.Y., J.J., J.E., B.L., D.W., J.A.M.S., and M.S., are employed by Revolution Medicines. The remaining authors declare no competing interests.
